文献速递糖尿病

单基因胰岛素缺乏型和胰岛素抵抗型糖尿病的精准诊疗:成就、前景与挑战

Achievements, prospects and challenges in precision care for monogenic insulin-deficient and insulin-resistant diabetes.
PubMed 文献 · Diabetologia · 2022-05-27

整合基因组等数据已开始以具有预后意义的方式对2型糖尿病进行分层,但尚未影响主流糖尿病实践。单基因缺陷所致糖尿病是精准糖尿病愿景的最佳范例。单基因糖尿病可分为原发性胰腺β细胞衰竭和原发性胰岛素抵抗,两组均已有基因型选择性治疗反应的明确例证,β细胞糖尿病的主要挑战在于大规模实施精准糖尿病愿景。

要点

  • 由致病性GCK突变所致糖尿病呈良性病程,常决定性地指导临床管理。
  • KCNJ11或ABCC8激活突变、或HNF1A或HNF4A功能缺失突变赋予磺脲类药物高反应性,常决定性地指导临床管理。
  • 单基因胰岛素抵抗型糖尿病中,皮下瘦素治疗对部分严重脂肪营养不良有益。

核心结论

  • 单基因糖尿病是迄今精准糖尿病愿景的最佳范例,β细胞糖尿病的主要挑战在于大规模实施该愿景。
  • 单基因胰岛素抵抗型糖尿病中基因型特异性获益迄今在远少数患者中得到证实,但更多基因型靶向治疗正在评估中。
  • 胰岛素抵抗亚组所建立的「脂肪衰竭」概念范式可能对常见2型糖尿病的精准治疗产生更广泛影响。

研究设计与样本

  • 综述,整合基因组及其他数据对糖尿病进行分层,聚焦单基因胰岛素缺乏型和胰岛素抵抗型糖尿病的精准诊疗。

主要发现

  • 由致病性GCK突变所致糖尿病呈良性病程,常决定性地指导临床管理。
  • KCNJ11或ABCC8激活突变、或HNF1A或HNF4A功能缺失突变赋予磺脲类药物高反应性,常决定性地指导临床管理。
  • 单基因胰岛素抵抗型糖尿病中,皮下瘦素治疗对部分严重脂肪营养不良有益。
  • 越来越多证据支持在脂肪营养不良者中使用「肥胖疗法」,即使其无肥胖。

局限性

  • 整合基因组等数据对2型糖尿病的分层尚未影响主流糖尿病实践。
  • 单基因胰岛素抵抗型糖尿病中基因型特异性获益迄今在远少数患者中得到证实。
  • 全基因组测序与单基因糖尿病的先前怀疑脱钩时,正迫使重新评估致病突变的重视程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Integration of genomic and other data has begun to stratify type 2 diabetes in prognostically meaningful ways, but this has yet to impact on mainstream diabetes practice. The subgroup of diabetes caused by single gene defects thus provides the best example to date of the vision of 'precision diabetes'. Monogenic diabetes may be divided into primary pancreatic beta cell failure, and primary insulin resistance. In both groups, clear examples of genotype-selective responses to therapy have been advanced. The benign trajectory of diabetes due to pathogenic GCK mutations, and the sulfonylurea-hyperresponsiveness conferred by activating KCNJ11 or ABCC8 mutations, or loss-of-function HNF1A or HNF4A mutations, often decisively guide clinical management. In monogenic insulin-resistant diabetes, subcutaneous leptin therapy is beneficial in some severe lipodystrophy. Increasing evidence also supports use of 'obesity therapies' in lipodystrophic people even without obesity. In beta cell diabetes the main challenge is now implementation of the precision diabetes vision at scale. In monogenic insulin-resistant diabetes genotype-specific benefits are proven in far fewer patients to date, although further genotype-targeted therapies are being evaluated. The conceptual paradigm established by the insulin-resistant subgroup with 'adipose failure' may have a wider influence on precision therapy for common type 2 diabetes, however. For all forms of monogenic diabetes, population-wide genome sequencing is currently forcing reappraisal of the importance assigned to pathogenic mutations when gene sequencing is uncoupled from prior suspicion of monogenic diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bonnefond A, Semple RK. Achievements, prospects and challenges in precision care for monogenic insulin-deficient and insulin-resistant diabetes. Diabetologia. 2022. PMID: 35618782. doi:10.1007/s00125-022-05720-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。